Lunit to provide AI solution for breast cancer to Singaporean hospital  

By Kim Joo-heon Posted : March 11, 2024, 10:48 Updated : July 22, 2024, 15:40
[Courtesy of Lunit]

SEOUL -- "Lunit INSIGHT MMG," a solution specializing in detecting breast cancer created by South Korea's medical artificial intelligence company Lunit, was adopted by a Singaporean hospital run by Southeast Asia's largest medical group IHH Healthcare. Starting with the contract with the healthcare group, which manages more than 20 hospitals in Southeast Asia, Lunit aims to expand its presence into other hospitals operated by IHH.

The adoption of Lunit INSIGHT MMG can increase work efficiency by replacing human experts, who are prone to making mistakes. This AI-based solution utilizes software to compare and analyze medical images of breast cancer patients and healthy individuals. When the solution detects an anomaly, human supervisors are notified, prompting additional tests for the patient. Lunit INSIGHT MMG has been successfully deployed overseas, including Taiwan and Saudi Arabia.

According to Lunit's datasets containing the analysis of 55,579 Swedish women who had received screening tests for breast cancer using Lunit INSIGHT MMG, the collaboration between a human doctor and the AI solution demonstrated a higher cancer detection rate (CDR) compared to the teamwork of two human workers. The solution's CDR stood at 4.3 per 1,000 people who received breast cancer screening, while the CDR by two human workers was 4.1.

Lunit said on March 11 that Lunit INSIGHT MMG will be provided to IHH Healthcare's Gleneagles Hospital Singapore. Gleneagles has 221 available beds. IHH Healthcare manages over 20 hospitals across Malaysia, Hong Kong, India, and China. "As demand for cutting-edge medical services continues to rise across East and Southeast Asia, Lunit is proud to spearhead the advancement of AI-powered solutions for cancer diagnostics in the region," Lunit CEO Brandon Suh said in a statement. 

Data released by market research firm MarketsandMarkets showed that the global diagnostic imaging market is projected to reach $35 billion by 2026. Meanwhile, Lunit also signed an agreement with Taiwan's Chung Shan Medical University to supply "Lunit INSIGHT CXR," another solution designed to detect chest conditions, including lung cancer. 

Copyright ⓒ Aju Press All rights reserved.

기사 이미지 확대 보기
닫기